Tardiff, Jil C. and Carrier, Lucie and Bers, Donald M. and Poggesi, Corrado and Ferrantini, Cecilia and Coppini, Raffaele and Maier, Lars S. and Ashrafian, Houman and Huke, Sabine and van der Velden, Jolanda (2015) Targets for therapy in sarcomeric cardiomyopathies. CARDIOVASCULAR RESEARCH, 105 (4). pp. 457-470. ISSN 0008-6363, 1755-3245
Full text not available from this repository. (Request a copy)Abstract
To date, no compounds or interventions exist that treat or prevent sarcomeric cardiomyopathies. Established therapies currently improve the outcome, but novel therapies may be able to more fundamentally affect the disease process and course. Investigations of the pathomechanisms are generating molecular insights that can be useful for the design of novel specific drugs suitable for clinical use. As perturbations in the heart are stage-specific, proper timing of drug treatment is essential to prevent initiation and progression of cardiac disease in mutation carrier individuals. In this review, we emphasize potential novel therapies which may prevent, delay, or even reverse hypertrophic cardiomyopathy caused by sarcomeric gene mutations. These include corrections of genetic defects, altered sarcomere function, perturbations in intracellular ion homeostasis, and impaired myocardial energetics.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; LATE SODIUM CURRENT; CARDIAC TROPONIN-T; PROTEIN-KINASE-II; DIASTOLIC HEART-FAILURE; MYOCARDIAL-PERFUSION ABNORMALITIES; CORONARY MICROVASCULAR DYSFUNCTION; RETICULUM CA2+ LEAK; END-STAGE PHASE; GREEN TEA; Hypertrophic cardiomyopathy; Dilated cardiomyopathy; Gene therapy; Ion channels; Energetics and microvasculature |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Petra Gürster |
| Date Deposited: | 20 Aug 2020 07:41 |
| Last Modified: | 20 Aug 2020 07:41 |
| URI: | https://pred.uni-regensburg.de/id/eprint/5692 |
Actions (login required)
 |
View Item |
